Patrick T. Higgins

Mr. Higgins joined the board of directors at Antios Therapeutics in February 2021, reuniting with his former Pharmasset colleague, Antios’ founder and Chairman, Dr. Abel De La Rosa. Mr. Higgins is a former biopharmaceutical executive who led companies in the development of therapies to treat infectious diseases of the liver, including Hepatitis B and C, for more than two decades. He was most recently chief operating officer at Arbutus Biopharma, which is developing therapeutics for HBV. Prior to Arbutus, he co-founded and served as chief executive officer of OnCore Biopharma, which he eventually took public by merging with Tekmira Pharmaceuticals to form Arbutus. Before co-founding OnCore, Mr. Higgins was executive vice president, Commercial, for Pharmasset, where he helped oversee the development of sofosbuvir, an FDA-approved therapy for HCV, and was responsible for developing and executing the commercial strategy for sofosbuvir before Pharmasset was acquired by Gilead Sciences in 2012 for $11 billion. Prior to Pharmasset, he led the infectious disease portfolio, including Pegasys® for hepatitis infections, for Hoffman-LaRoche and spent 13 years at Schering Plough in various roles.

Mr. Higgins is currently also a director on the Board of Saronic Biotechnology. He earned is B.A. at Villanova University and his M.B.A. at Seton Hall University.